Пролиферативная активность и рецепторный статус доброкачественных и пограничных эпителиальных опухолей яичников

The aim was to study the expression features of proliferation marker Ki-67 and estrogen receptor (ER) in cells of benign (BeEOT) and borderline epithelial ovarian tumors (BoEOT) and to determine their value for clinical prognosis and tumor justification tactics for further treatment. Patients and methods . Studies conducted on the material of 60 patients with BeEOT and BoEOT who underwent examination and treatment during 2010-2016. It was studied specific menstrual dysfunction, ultrasound data and colour doppler research, the performance of serum tumor markers, morphological and immunohistochemical studies were conducted to determine the Ki-67 and ER in samples of BeEOT and BoEOT. Results . The results of Ki-67 expression determining indicate the heterogeneity of individual performance fluctuations from 0% to 15%. The average value of the proliferation index (PI) was 5.07±0.47%, the median (ME) was 4%. It is determined that almost all BeEOT (96.7%) was marked by lower PI<10%, while 5 of 10 serous borderline cystadenomas (50%) and 1 of 10 mucinous borderline cystadenomas (10%) were attributed to high proliferation (IPі10%) tumors. It is found that in most cells of BeEOT and BoEOT was available the expression of ER. Individual values of ER expression level ranged from 2.0% to 90,0%. The average value of the IM (index marks) ER was 45.08±3.2%, ME=49.5%. It is found a significant decrease (p<0.05) in the ER expression level in EOT of late reproductive age patients compared with younger ones, as well as in cells of BoEOT compared to BeEOT. Conclusion. Some associative connection between the expression of Ki-67 and ER with EOT malignancy potential demonstrates the need to use them for tumor course prognosis and appointment of adequate individualized treatment strategy of patients. Key words: benign and borderline ovarian tumors, immunohistochemical studies, Ki-67, estrogen receptors.